John M. Maris, MD

Grossmann LD, Chen CH, Uzun Y, Thadi A, Wolpaw AJ, Louault K, Goldstein Y, Surrey LF, Martinez D, Calafatti M, Gerelus M, Gao P, Lee L, Patel K, Kaufman RS, Shani G, Farrel A, Moshitch-Moshkovitz S, Grimaldi P, Shapiro M, Kendsersky NM, Lindsay JM, Casey CE, Krytska K, Scolaro L, Tsang M, Groff D, Matkar S, Kalna JR, Mycek E, McDevitt J, Runbeck E, Patel T, Bernt KM, Asgharzadeh S, DeClerck YA, Mosse YP, Tan K, Maris JM. Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells. Cancer Discov. 2024;14(12):2387-406.

Bosse KR, Giudice AM, Lane MV, McIntyre B, Schurch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Tierno MB, Oxnard GR, Maris JM, Mosse YP. Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer Discov. 2022;12(12):2800-19. Epub 2022/09/16. doi: 10.1158/2159-8290.CD-22-0287. PubMed PMID: 36108156; PMCID: PMC9722579.

Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM.: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature. Nov 2021; PMID: 34732890. Notes: doi: 10.1038/s41586-021-04061-6

Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, Capasso M, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SF, Li H, Hakonarson H. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008 Jun 12;358(24):2585-93. PubMed PMID: 18463370; PubMed Central PMCID: PMC2742373.

Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5. PubMed PMID: 18724359; PubMed Central PMCID: PMC2672043.

2025

Kendsersky NM, Odrobina M, Mabe NW, Farrel A, Grossmann L, Tsang M, Groff D, Wolpaw AJ, Narch A, Zammarchi F, van Berkel PH, Dang CV, Mosse YP, Stegmaier K, Maris JM. Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets. Neuro Oncol. 2025.

Berko ER, Naranjo A, Daniels AA, McNulty SN, Krytska K, Druley T, Zelley K, Koneru B, Chen L, Polkosnik G, Irwin MS, Bagatell R, Maris JM, Reynolds CP, DuBois SG, Park JR, Mosse YP. Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. J Clin Oncol. 2025:JCO2402407.

Shraim R, Mooney B, Conkrite KL, Hamilton AK, Morin GB, Sorensen PH, Maris JM, Diskin SJ, Sacan A. ImmunoTar-integrative prioritization of cell surface targets for cancer immunotherapy. Bioinformatics. 2025.

Matkar S, East MP, Stuhlmiller TJ, Witek G, Farrel A, Pastor S, Okumu DO, Kennedy A, Kalna JR, Berko ER, Casey CE, Krytska K, Patel K, Rokita JL, Gerelus M, Maris JM, Johnson GL, Mosse YP. Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma. Mol Cancer Ther. 2025.

Voeller J, Katzenstein HM, Naranjo A, Tenney SC, Chen L, London WB, Handler MH, Schmidt ML, Shimada H, Hogarty MD, Gastier-Foster J, Park JR, Cohn SL, Maris JM, Bagatell R, Twist CJ. Outcomes of patients with intermediate-risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatr Blood Cancer. 2025;72(1):e31407.

Brown EG, Adkins ES, Mattei P, Hoffer FA, Wootton-Gorges SL, London WB, Naranjo A, Schmidt ML, Hogarty MD, Irwin MS, Cohn SL, Park JR, Maris JM, Bagatell R, Twist CJ, Nuchtern JG, Davidoff AM, Newman EA, Lal DR. Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Pediatr Surg. 2025;60(1):161896.

Geng Z, Wafula E, Corbett RJ, Zhang Y, Jin R, Gaonkar KS, Shukla S, Rathi KS, Hill D, Lahiri A, Miller DP, Sickler A, Keith K, Blackden C, Chroni A, Brown MA, Kraya AA, Rood BR, Resnick AC, Van Kuren N, Maris JM, Farrel A, Koptyra MP, Trooskin GR, Coleman N, Zhu Y, Stefankiewicz S, Abdullaev Z, Chinwalla AT, Santi M, Naqvi AS, Mason JL, Koschmann CJ, Huang X, Diskin SJ, Aldape K, Farrow BK, Ma W, Zhang B, Ennis BM, Tasian S, Phul S, Lueder MR, Zhong C, Dybas JM, Wang P, Taylor D, Rokita JL. The Open Pediatric Cancer Project. bioRxiv. 2025.

Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, Biswas R, Yu Y, Shrock EL, Ault R, Leung PJY, Huang B, Goreshnik I, Tam J, Carr KD, Singer B, Criswell C, Wicky BIM, Vafeados D, Sanchez MG, Kim HM, Vazquez Torres S, Chan S, Sun SM, Spear T, Sun Y, O'Reilly K, Maris JM, Sgourakis NG, Melnyk RA, Liu CC, Baker D. Atomically accurate de novo design of antibodies with RFdiffusion. bioRxiv. 2025.

Yu W, Biyik-Sit R, Uzun Y, Chen CH, Thadi A, Sussman JH, Pang M, Wu CY, Grossmann LD, Gao P, Wu DW, Yousey A, Zhang M, Turn CS, Zhang Z, Bandyopadhyay S, Huang J, Patel T, Chen C, Martinez D, Surrey LF, Hogarty MD, Bernt K, Zhang NR, Maris JM, Tan K. Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring. Nat Genet. 2025.

Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, Fleurence J, Sweidan R, Wang T, Zhang H, Masand P, Maris JM, Martinez D, Pogoriler J, Varadarajan N, Thakkar SG, Lyon D, Lapteva N, Zhuyong M, Patel K, Lopez-Terrada D, Ramos CA, Lulla P, Armaghany T, Grilley BJ, Gottschalk S, Dotti G, Metelitsa LS, Heslop HE, Brenner MK, Sumazin P, Heczey A. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940-6.

2024

Felipe I, Villarreal JMd, Patel K, Martinez-Torrecuadrada JL, Grossmann LD, Roncador G, Cubells M, Farrel A, Nathan K, Sabroso-Lasa S, Sancho-Trevino L, Torres K, Martinez D, Munoz-Peralta J, Garcia F, Pogoriler J, Moreno L, Maris J, Real FX. BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states. bioRxiv. 2024:2024.02.11.579816.

Schoeman S, Bagatell R, Cahill AM, Maris J, Mattei P, Mosse Y, Pogoriler J, Srinivasan A, Acord M. Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single-center retrospective study. Pediatr Blood Cancer. 2024;71(4):e30887.

Cheng B, Fang W, Pastor S, March AR, Porras T, Wu HW, Velez M, Parekh C, Maris JM, Asgharzadeh S, Huang M. Comparison of human pluripotent stem cell differentiation protocols to generate neuroblastoma tumors. Sci Rep. 2024;14(1):23050.

Smith MA, Houghton PJ, Lock RB, Maris JM, Gorlick R, Kurmasheva RT, Li XN, Teicher BA, Chuang JH, Dela Cruz FS, Dyer MA, Kung AL, Lloyd MW, Mosse YP, Stearns TM, Stewart EA, Bult CJ, Erickson SW. Lessons learned from 20 years of preclinical testing in pediatric cancers. Pharmacol Ther. 2024;264:108742.

Grossmann LD, Chen CH, Uzun Y, Thadi A, Wolpaw AJ, Louault K, Goldstein Y, Surrey LF, Martinez D, Calafatti M, Gerelus M, Gao P, Lee L, Patel K, Kaufman RS, Shani G, Farrel A, Moshitch-Moshkovitz S, Grimaldi P, Shapiro M, Kendsersky NM, Lindsay JM, Casey CE, Krytska K, Scolaro L, Tsang M, Groff D, Matkar S, Kalna JR, Mycek E, McDevitt J, Runbeck E, Patel T, Bernt KM, Asgharzadeh S, DeClerck YA, Mosse YP, Tan K, Maris JM. Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells. Cancer Discov.

Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, Wang L, Asgharzadeh S, Park J, Gustafson WC, Matthay KK, Maris JM, Weiss WA. ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell reports. 2024;43(3):113927.

Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. 2024;42(11):1970-82 e7.

Gilbertson RJ, Behjati S, Bottcher AL, Bronner ME, Burridge M, Clausing H, Clifford H, Danaher T, Donovan LK, Drost J, Eggermont AMM, Emerson C, Flores MG, Hamerlik P, Jabado N, Jones A, Kaessmann H, Kleinman CL, Kool M, Kutscher LM, Lindberg G, Linnane E, Marioni JC, Maris JM, Monje M, Macaskill A, Niederer S, Northcott PA, Peeters E, Plieger-van Solkema W, Preussner L, Rios AC, Rippe K, Sandford P, Sgourakis NG, Shlien A, Smith P, Straathof K, Sullivan PJ, Suva ML, Taylor MD, Thompson E, Vento-Tormo R, Wainwright BJ, Wechsler-Reya RJ, Westermann F, Winslade S, Al-Lazikani B, Pfister SM. The Virtual Child. Cancer Discov. 2024;14(4):663-8.

Weiner AK, Palmer A, Moll MF, Lindberg G, Reidy K, Diskin SJ, Mackall CL, Maris JM, Sullivan PJ. Advancing childhood cancer research through young investigator and advocate collaboration. Pediatr Blood Cancer. 2024;71(9):e31127.

2023

Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung JT, London WB, Shulkin BL, Mathew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park J, Yu AL, Sondel PM, Bagatell R. KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group. J Immunother Cancer. 2023;11(2). Epub 2023/02/24. doi: 10.1136/jitc-2022-006530. PubMed PMID: 36822669.

Kim J, Vaksman Z, Egolf LE, Kaufman R, Evans JP, Conkrite KL, Danesh A, Lopez G, Randall MP, Dent MH, Farra LM, Menghani N, Dymek M, Desai H, Hausler R, Penn Medicine B, Regeneron Genetics C, Cancer Genomics Research L, Auvil JG, Gerhard DS, Hakonarson H, Maxwell KN, Cole KA, Pugh TJ, Bosse KR, Khan J, Wei JS, Maris JM, Stewart DR, Diskin SJ. Germline pathogenic variants in 786 neuroblastoma patients. medRxiv. 2023. Epub 2023/02/08. doi: 10.1101/2023.01.23.23284864. PubMed PMID: 36747619; PMCID: PMC9901064.

Randall MP, Egolf LE, Vaksman Z, Samanta M, Tsang M, Groff D, Evans JP, Rokita JL, Layeghifard M, Shlien A, Maris JM, Diskin SJ, Bosse KR. BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. bioRxiv. 2023. Epub 2023/02/14. doi: 10.1101/2023.01.31.525066. PubMed PMID: 36778420; PMCID: PMC9915690.

Cole KA, Ijaz H, Surrey LF, Santi M, Liu X, Minard CG, Maris JM, Voss S, Reid JM, Fox E, Weigel BJ. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 2023. Epub 2023/04/21. doi: 10.1002/cncr.34786. PubMed PMID: 37081608.

Weichert-Leahey N, Shi H, Tao T, Oldridge DA, Durbin AD, Abraham BJ, Zimmerman MW, Zhu S, Wood AC, Reyon D, Joung JK, Young RA, Diskin SJ, Maris JM, Look AT. Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state. J Clin Invest. 2023;133(10). Epub 2023/05/15. doi: 10.1172/JCI166919. PubMed PMID: 37183825.

Bender HG, Irwin MS, Hogarty MD, Castleberry R, Maris JM, Kao PC, Zhang FF, Naranjo A, Cohn SL, London WB. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023:JCO2201946. Epub 2023/04/25. doi: 10.1200/JCO.22.01946. PubMed PMID: 37098238.

Maris JM. In memoriam: Dr. Audrey E. Evans. Pediatr Blood Cancer. 2023;70(3):e30113. Epub 2022/12/17. doi: 10.1002/pbc.30113. PubMed PMID: 36524612.

Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mosse YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023. Epub 2023/04/04. doi: 10.1038/s41591-023-02297-5. PubMed PMID: 37012551.

Berko ER, Witek GM, Matkar S, Petrova ZO, Wu MA, Smith CM, Daniels A, Kalna J, Kennedy A, Gostuski I, Casey C, Krytska K, Gerelus M, Pavlick D, Ghazarian S, Park JR, Marachelian A, Maris JM, Goldsmith KC, Radhakrishnan R, Lemmon MA, Mossé YP. Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nat Commun. 2023;14(1):2601. doi: 10.1038/s41467-023-38195-0.

Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma. Pediatr Blood Cancer. 2023:e30743.

Coppes MJ, Maris JM. Dr Audrey E. Evans (1925-2022): academic trailblazer par excellence. Pediatr Res. 2023;93(7):1788-9.

Farrel A, Li P, Veenbergen S, Patel K, Maris JM, Leonard WJ. ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery. BMC Bioinformatics. 2023;24(1):303.

Modi A, Lopez G, Conkrite KL, Su C, Leung TC, Ramanan S, Manduchi E, Johnson ME, Cheung D, Gadd S, Zhang J, Smith MA, Guidry Auvil JM, Meshinchi S, Perlman EJ, Hunger SP, Maris JM, Wells AD, Grant SFA, Diskin SJ. Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors. Cancer Res. 2023;83(20):3462-77.

Mooney B, Negri GL, Shyp T, Delaidelli A, Zhang HF, Spencer Miko SE, Weiner AK, Radaoui AB, Shraim R, Lizardo MM, Hughes CS, Li A, El-Naggar AM, Rouleau M, Li W, Dimitrov DS, Kurmasheva RT, Houghton PJ, Diskin SJ, Maris JM, Morin GB, Sorensen PH. Surface and global proteome analyses identify ENPP1 and other surface proteins as actionable immunotherapeutic targets in Ewing sarcoma. Clin Cancer Res. 2023.

Rosenberg MI, Greenstein E, Buchkovich M, Peres A, Santoni-Rugiu E, Yang L, Mikl M, Vaksman Z, Gibbs DL, Reshef D, Salovin A, Irwin MS, Naranjo A, Ulitsky I, de Alarcon PA, Matthay KK, Weigman V, Yaari G, Panzer JA, Friedman N, Maris JM. Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma. Cell reports. 2023;42(8):112879.

Sun Y, Florio TJ, Gupta S, Young MC, Marshall QF, Garfinkle SE, Papadaki GF, Truong HV, Mycek E, Li P, Farrel A, Church NL, Jabar S, Beasley MD, Kiefel BR, Yarmarkovich M, Mallik L, Maris JM, Sgourakis NG. Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion. Sci Immunol. 2023;8(90):eadj5792.

Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell Rep Med. 2023:101212.

Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2023;623(7988):820-7.

Zhang HF, Delaidelli A, Javed S, Turgu B, Morrison T, Hughes CS, Yang X, Pachva M, Lizardo MM, Singh G, Hoffmann J, Huang YZ, Patel K, Shraim R, Kung SHY, Morin GB, Aparicio S, Martinez D, Maris JM, Bosse KR, Williams KC, Sorensen PH. A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma. Sci Adv. 2023;9(34):eadg6693.

2022

Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine. 2022 Jan; 28(1): 125-135. PMID: 34992263 Notes: doi: 10.1038/s41591-021-01581-6.

Ferris MA, Smith AM, Heath SE, Duncavage EJ, Oberley MJ, Freyer D, Wynn R, Douzgou S, Maris JM, Reilly AF, Wu M, Choo F, Fiets RB, Koene S, Spencer DH, Miller CA, Shinawi M, Ley TJ.: DNMT3A Overgrowth Syndrome is associated with the development of hematopoietic malignancies in children and young adults. Blood. 2022 Jan; 139(3): 461-464. PMID: 34788385. Notes: Epub Nov 2021. doi: 10.1182/blood.2021014052.

Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S, Pascual-Pasto G, Garrigan E, Xu P, Huang J, Salzer B, Delaidelli A, Raman S, Cui H, Martinez B, Bornheimer SJ, Sahaf B, Alag A, Fetahu IS, Hasselblatt M, Parker KR, Anbunathan H, Hwang J, Huang M, Sakamoto K, Lacayo NJ, Klysz DD, Theruvath J, Vilches-Moure JG, Satpathy AT, Chang HY, Lehner M, Taschner-Mandl S, Julien JP, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022 Jan; 40(1): 53-69. PMID: 34971569. Notes: doi: 10.1016/j.ccell.2021.12.005. Epub 2021 Dec 30.

Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, Arsenian-Henriksson M, Powell DJ Jr, Bosse KR, Kossenkov A, Tan K, Hogarty MD, Maris JM, Dang CV. Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America. 2022 Feb 8; 119(6). PMID: 35121657.

Testori A, Vaksman Z, Diskin SJ, Hakonarson H, Capasso M, Iolascon A, Maris JM, Devoto M. Genetic analysis in African American children supports ancestry specific neuroblastoma susceptibility. Cancer Epidemiol Biomarkers Prev. 2022 April; 31(4): 870-875. PMID: 35131881. Notes: doi: 10.1158/1055-9965.EPI-21-0782. Epub 2022 Feb.

Chang X, Liu Y, Glessner J, Hou C, Qu H, Nguyen K, Sleiman P, Lee L, Diskin SJ, Maris JM, Hakonarson H.: Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma. J Natl Cancer Inst. June 2022. Notes: doi: 10.1093/jnci/djac012. Epub 2022 Feb. PMID: 35134187.

Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, Ranieri P, Tsang M, Hou C, Li Y, Pawel B, Martinez D, Vaidyanathan G, Carlin S, Pryma DA, Maris JM. Preclinical development of [211At]meta-astatobenzylguanidine ([211At]MABG) as an alpha particle radiopharmaceutical therapy for neuroblastoma. Clinical Cancer Research. 2022 Sept 15; 28(18): 4147-4157. Epub July 2022. PMID: 35861867.

Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report from the Children's Oncology Group. Journal of Clinical Oncology. 2022 July; online ahead of print. PMID: 35839426.

Lalchungnunga H, Hao W, Maris JM, Asgharzadeh S, Henrich KO, Westermann F, Tweddle DA, Schwalbe EC, Strathdee G.: Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma. Br J Cancer. 2022 Sep29.doi: 10.1038/s41416-022-01988-z. Online ahead of print. PMID: 36175618.

Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, Lane MV, Buongervino SN, Smith T, Madsen PJ, Martinez D, Delaidelli A, Sorensen PH, Wechsler-Reya RJ, Karikó K, Storm PB, Barrett DM, Resnick AC, Maris JM, Bosse KR. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. Journal of Immunotherapy Cancer. 2022 Sep;10(9):e004450. doi: 10.1136/jitc-2021-004450. PMID: 36167467.

Lynch HM, Beslow LA, Treat JR, Corcoran A, Lin JH, Gunawardena N, Maris JM, Behrens EM. Paraneoplastic myasthenia gravis and pemphigus associated with follicular dendritic cell sarcoma leading to cardiorespiratory collapse in a 7-year-old. Pediatric Blood Cancer. 2022 Nov;69(11):e29723. doi: 10.1002/pbc.29723. Epub 2022 Apr 29. PMID: 35484988.

Bosse KR, Giudice AM, Lane MV, McIntyre B, Schurch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Brisson Tierno M, Oxnard GR, Maris JM, Mosse YP. Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma. Cancer Discovery . 2022 Sep 15; Online ahead of print. PMID: 36108156

Makvandi M, Samanta M, Martorano P, Lee H, Gitto SB, Patel K, Groff D, Pogoriler J, Martinez D, Riad A, Dabagian H, Zaleski M, Taghvaee T, Xu K, Lee JY, Hou C, Farrel A, Batra V, Carlin SD, Powell DJ, Jr., Mach RH, Pryma DA, Maris JM. Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Commun Biol. 2022;5(1):1260. Epub 2022/11/19. doi: 10.1038/s42003-022-04209-8. PubMed PMID: 36396952.

Bosse KR, Giudice AM, Lane MV, McIntyre B, Schurch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Tierno MB, Oxnard GR, Maris JM, Mosse YP. Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer Discov. 2022;12(12):2800-19. Epub 2022/09/16. doi: 10.1158/2159-8290.CD-22-0287. PubMed PMID: 36108156; PMCID: PMC9722579.

Coppes MJ, Maris JM. Dr Audrey E. Evans (1925-2022): Academic trailblazer par excellence. Pediatr Res. 2022. Epub 2022/11/06. doi: 10.1038/s41390-022-02368-2. PubMed PMID: 36335266.

Krytska K, Casey CE, Pogoriler J, Martinez D, Rathi KS, Farrel A, Berko ER, Tsang M, Sano RR, Kendsersky N, Erickson SW, Teicher BA, Isse K, Saunders L, Smith MA, Maris JM, Mosse YP. Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma. Cancer Res Commun. 2022;2(7):616-23. Epub 2022/11/17. doi: 10.1158/2767-9764.crc-22-0137. PubMed PMID: 36381237; PMCID: PMC9648412.

2021

Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Durno C, Malkin D, Maris JM, Taylor MD, Shlien A, Pugh TJ, Ohashi PS, Hawkins CE, Tabori U. Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition. Cancer Discov. June 2021; 11(6): 1454-1467. Epub 2021/02/11. doi: 10.1158/2159-8290.CD-20-1050. PubMed PMID: 33563663.

Dabagian H, Taghvaee T, Martorano P, Martinez D, Samanta M, Watkins CM, Chai R, Mansfield A, Graham TJ, Maris JM, Pryma DA, Mach RH, Makvandi M. PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma. ACS Pharmacol Transl Sci. 2021;4(1):344-51. Epub 2021/02/23. doi: 10.1021/acsptsci.0c00206. PubMed PMID: 33615184; PMCID: PMC7887847 D.A.P., and M.M. are inventor and co-inventors on a pending patent for a 211At-PARP targeted radiotherapy. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Dong Z, Yeo KS, Lopez G, Zhang C, Dankert Eggum EN, Rokita JL, Ung CY, Levee TM, Her ZP, Howe CJ, Hou X, van Ree JH, Li S, He S, Tao T, Fritchie K, Torres-Mora J, Lehman JS, Meves A, Razidlo GL, Rathi KS, Weroha SJ, Look AT, van Deursen JM, Li H, Westendorf JJ, Maris JM, Zhu S. GAS7 Deficiency Promotes Metastasis in MYCN-driven Neuroblastoma. Cancer Res. June 2021. Epub 2021/02/20. doi: 10.1158/0008-5472.CAN-20-1890. PubMed PMID: 33602789. 377. Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clin Cancer Res. May 2021; 27(10): 2938-2946. Epub 2021/02/22. doi: 10.1158/1078-0432.CCR-20-4221. PubMed PMID: 33619171.

Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021;146:115-24. Epub 2021/02/19. doi: 10.1016/j.ejca.2021.01.018. PubMed PMID: 33601323.

Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, Pogoriler J, Rathi KS, Patel SA, Oristian KM, Linardic CM, Maris JM, Haynes KA, Schnepp RW. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Mol Oncol. August 2021. Epub 2021/02/02. doi: 10.1002/1878-0261.12914. PubMed PMID: 33523558.

Turgu B, Zhang F, El-Naggar A, Negri GL, Kogler M, Tortola L, Johnson F, Ng T, Li A, Yapp D, Lockwood W, Martinez D, Maris JM, Daugaard M, Penninger JM, Hughes CS, Sorensen PH. HACE1 blocks HIF1alpha accumulation under hypoxia in a RAC1 dependent manner. Oncogene. March 2021;40(11):1988-2001. Epub 2021/02/20. doi: 10.1038/s41388-021-01680-1. PubMed PMID: 33603169; PMCID: PMC7979542.

Wolpaw AJ, Bayliss R, Buchel G, Dang CV, Eilers M, Gustafson WC, Hansen GH, Jura N, Knapp S, Lemmon MA, Levens D, Maris JM, Marmorstein R, Metallo SJ, Park JR, Penn LZ, Rape M, Roussel MF, Shokat KM, Tansey WP, Verba KA, Vos SM, Weiss WA, Wolf E, Mosse YP. Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Res. April 2021. Epub 2021/01/30. doi: 10.1158/0008-5472.CAN-20-3108. PubMed PMID: 33509943.

Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. April 2021;27(8):2179-89. Epub 2021/01/29. doi: 10.1158/1078-0432.CCR-20-3909. PubMed PMID: 33504555; PMCID: PMC8046731

Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD.: Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med May 2021. PMID: 32341580.

Kendsersky NM, Lindsay JM, Kolb EA, Smith MA, Teicher BA, Erickson S, Earley EJ, Mossé YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, St Croix B, Gorlick R, Kurmasheva RT, Houghton PJ, Maris JM.: The B7-H3-targeting antibody-drug conjugate m276- SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clin Cancer Res. 27(10): 2938-2946, May 2021 Notes: doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. PMID: 33619171.

Campbell BB, Galati MA, Stone SC, Riemenschneider AN, Edwards M, Sudhaman S, Siddaway R, Komosa M, Nunes NM, Nobre L, Morrissy AS, Zatzman M, Zapotocky M, Joksimovic L, Kalimuthu SN, Samuel D, Mason G, Bouffet E, Morgenstern DA, Aronson M, Durno C, Malkin D, Maris JM, Taylor MD, Shlien A, Pugh TJ, Ohashi PS, Hawkins CE, Tabori U.: Mutations in the RAS/MAPK pathway drive replication repair deficient hypermutated tumors and confer sensitivity to MEK inhibition. Cancer Discov. 2021 June; 11(6): 1454-1467. Notes: doi: 10.1158/2159-8290.CD-20-1050. Epub 2021 Feb 9. PMID: 33563663.

Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR.: A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Rep Med. 2021 July; 2(7). PMID: 34337560.

Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, Pogoriler J, Rathi KS, Patel SA, Oristian KM, Linardic CM, Maris JM, Haynes KA, Schnepp RW.: Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Mol Oncol. 2021 Aug; 15(8): 2156-2171. Notes: doi: 10.1002/1878-0261.12914. Epub 2021 Mar 27. PMID: 335235558.

Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H.: Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 Aug; 45(8): 1075-1081, PMID: 33739795.

Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM.: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature. Nov 2021; PMID: 34732890. Notes: doi: 10.1038/s41586-021-04061-6

2020

Bosse KR, Majzner RG, Mackall CL, Maris JM. Immune-Based Approaches for the Treatment of Pediatric Malignancies. Annual Review of Cancer Biology. 2020;4:353-70.

Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, Bagashev A, Taylor D, Mourelatos Z, Grupp SA, Barrett D, Maris JM, Sotillo E, Barash Y, Thomas-Tikhonenko A. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34(4):1202-7. Epub 2019/10/09. doi: 10.1038/s41375-019-0580-z. PubMed PMID: 31591467.

Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clin Cancer Res. 2020;26(6):1213-9. Epub 2019/12/21. doi: 10.1158/1078-0432.CCR-19-3470. PubMed PMID: 31857431; PMCID: PMC7073289.

Balci TB, Strong A, Kalish JM, Zackai E, Maris JM, Reilly A, Surrey LF, Wertheim GB, Marcadier JL, Graham GE, Carter MT. Tatton-Brown-Rahman syndrome: Six individuals with novel features. Am J Med Genet A. 2020;182(4):673-80. Epub 2020/01/22. doi: 10.1002/ajmg.a.61475. PubMed PMID: 31961069.

Kolb EA, Houghton PJ, Kurmasheva RT, Mosse YP, Maris JM, Erickson SW, Guo Y, Teicher BA, Smith MA, Gorlick R. Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatr Blood Cancer. 2020;67(5):e28098. Epub 2020/01/25. doi: 10.1002/pbc.28098. PubMed PMID: 31975571.

Li Y, Gruber JJ, Litzenburger UM, Zhou Y, Miao YR, LaGory EL, Li AM, Hu Z, Yip M, Hart LS, Maris JM, Chang HY, Giaccia AJ, Ye J. Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia. Cell Death Dis. 2020;11(2):102. Epub 2020/02/08. doi: 10.1038/s41419-020-2303-9. PubMed PMID: 32029721; PMCID: PMC7005271.

Chang X, Bakay M, Liu Y, Glessner J, Rathi KS, Hou C, Qu H, Vaksman Z, Nguyen K, Sleiman PMA, Diskin SJ, Maris JM, Hakonarson H. Mitochondrial DNA haplogroups and susceptibility to neuroblastoma. J Natl Cancer Inst. 2020. Epub 2020/02/26. doi: 10.1093/jnci/djaa024. PubMed PMID: 32096864.

Reaman G, Stancato L, Vassal G, Maris JM. Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2020;40:1-8. Epub 2020/03/25. doi: 10.1200/EDBK_278893. PubMed PMID: 32207673.

Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM. CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. Front Oncol. 2020;10:302. Epub 2020/03/27. doi: 10.3389/fonc.2020.00302. PubMed PMID: 32211329; PMCID: PMC7069022. 360. Yarmarkovich M, Farrel A, Sison A, di Marco M, Raman P, Parris JL, Monos D, Lee H, Stevanovic S, Maris JM. Immunogenicity and Immune Silence in Human Cancer. Frontiers in Immunology. 2020;11(69). doi: 10.3389/fimmu.2020.00069.

Upton K, Modi A, Patel K, Kendsersky NM, Conkrite KL, Sussman RT, Way GP, Adams RN, Sacks GI, Fortina P, Diskin SJ, Maris JM, Rokita JL. Epigenomic profiling of neuroblastoma cell lines. Sci Data. 2020;7(1):116. Epub 2020/04/15. doi: 10.1038/s41597-020-0458-y. PubMed PMID: 32286315; PMCID: PMC7156688.

Healy JR, Hart LS, Shazad AL, Gagliardi ME, Tsang M, Elias J, Ruden J, Farrel A, Rokita JL, Li Y, Wyce A, Barbash O, Batra V, Samanta M, Maris JM, Schnepp RW. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. Pediatr Blood Cancer. 2020;67(6):e28267. Epub 2020/04/21. doi: 10.1002/pbc.28267. PubMed PMID: 32307821; PMCID: PMC7188563.

Overall SA, Toor JS, Hao S, Yarmarkovich M, Sara MOR, Morozov GI, Nguyen S, Japp AS, Gonzalez N, Moschidi D, Betts MR, Maris JM, Smibert P, Sgourakis NG. High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange. Nat Commun. 2020;11(1):1909. Epub 2020/04/22. doi: 10.1038/s41467-020-15710-1. PubMed PMID: 32312993; PMCID: PMC7170893.

Chen D, Cox J, Annam J, Weingart M, Essien G, Rathi KS, Rokita JL, Khurana P, Cuya SM, Bosse KR, Pilgrim A, Li D, Shields C, Laur O, Maris JM, Schnepp RW. LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. Neoplasia. 2020;22(6):231-41. Epub 2020/04/28. doi: 10.1016/j.neo.2020.04.001. PubMed PMID: 32339949.

Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, Przelicki D, Richman C, Ramaswamy V, Daniels C, Pallota JG, Douglas T, Joynt ACM, Haapasalo J, Nor C, Vladoiu MC, Kuzan-Fischer CM, Garzia L, Mack SC, Varadharajan S, Baker ML, Hendrikse L, Ly M, Kharas K, Balin P, Wu X, Qin L, Huang N, Stucklin AG, Morrissy AS, Cavalli FMG, Luu B, Suarez R, De Antonellis P, Michealraj A, Rastan A, Hegde M, Komosa M, Sirbu O, Kumar SA, Abdullaev Z, Faria CC, Yip S, Hukin J, Tabori U, Hawkins C, Aldape K, Daugaard M, Maris JM, Sorensen PH, Ahmed N, Taylor MD. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020. Epub 2020/04/29. doi: 10.1038/s41591-020-0827-2. PubMed PMID: 32341580.

Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol. 2020:JCO2000203. Epub 2020/04/29. doi: 10.1200/JCO.20.00203. PubMed PMID: 32343642.

Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, Modi A, Rokita JL, Urias E, Hindle A, Davidson H, McCoy K, Nance J, Yazdani V, Irwin MS, Yang S, Wheeler DA, Maris JM, Diskin SJ, Reynolds CP. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020;80(12):2663-75. Epub 2020/04/16. doi: 10.1158/0008-5472.CAN-19-3068. PubMed PMID: 32291317; PMCID: PMC7313726.

Lopez G, Conkrite KL, Doepner M, Rathi KS, Modi A, Vaksman Z, Farra LM, Hyson E, Noureddine M, Wei JS, Smith MA, Asgharzadeh S, Seeger RC, Khan J, Auvil JG, Gerhard DS, Maris JM, Diskin SJ. Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma. Genome Res. 2020. Epub 2020/08/17. doi: 10.1101/gr.252106.119. PubMed PMID: 32796005.

Yarmarkovich M, Warrington JM, Farrel A, Maris JM. Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity. Cell Rep Med. 2020;1(3):100036. Epub 2020/08/25. doi: 10.1016/j.xcrm.2020.100036. PubMed PMID: 32835302; PMCID: PMC7276303.

Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. August 2021; 45(8):1075-1081. Epub 2021/03/20. doi: 10.1097/PAS.0000000000001647. PubMed PMID: 33739795.

Lee H, Riad A, Martorano P, Mansfield A, Samanta M, Batra V, Mach RH, Maris JM, Pryma DA, Makvandi M. PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. J Nucl Med. 2020;61(6):850-6. Epub 2019/11/05. doi: 10.2967/jnumed.119.233965. PubMed PMID: 31676730; PMCID: PMC7262217.

Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav S, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020;136:52-68. Epub 2020/07/13. doi: 10.1016/j.ejca.2020.05.010. PubMed PMID: 32653773.

Grossmann LD, Maris JM. Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles. Mol Oncol. February 2021;15(2):347-9. Epub 2020/12/15. doi: 10.1002/1878-0261.12880. PubMed PMID: 33314654; PMCID: PMC7858281.

2019

Maris JM, Perilongo G. Giulio J. D'Angio, MD, 1922-2018. Pediatr Blood Cancer. 2019;66(1):e27508. Epub 2018/10/24. doi: 10.1002/pbc.27508. PubMed PMID: 30350927.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clin Cancer Res. 2019;25(7):2278-89. Epub 2018/12/20. doi: 10.1158/1078-0432.CCR-18-2728. PubMed PMID: 30563935; PMCID: PMC6445779.

Coppes MJ, Maris JM. Dr. Giulio J. D'Angio (1922-2018). Pediatr Res. 2019;85(6):752-3. Epub 2019/02/14. doi: 10.1038/s41390-019-0328-5. PubMed PMID: 30755712.

Heitzeneder S, Sotillo E, Shern JF, Sindiri S, Xu P, Jones R, Pollak M, Noer PR, Lorette J, Fazli L, Alag A, Meltzer P, Lau C, Conover CA, Oxvig C, Sorensen PH, Maris JM, Khan J, Mackall CL. Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. J Natl Cancer Inst. 2019. Epub 2019/01/31. doi: 10.1093/jnci/djy209. PubMed PMID: 30698726.

Makvandi M, Lee H, Puentes LN, Reilly SW, Rathi KS, Weng CC, Chan HS, Hou C, Raman P, Martinez D, Xu K, Carlin SD, Greenberg RA, Pawel BR, Mach RH, Maris JM, Pryma DA. Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Mol Cancer Ther. 2019;18(7):1195-204. Epub 2019/05/11. doi: 10.1158/1535-7163.MCT-18-0837. PubMed PMID: 31072830; PMCID: PMC6606392

Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019;37(2):115-24. Epub 2018/11/18. doi: 10.1200/JCO.18.00419. PubMed PMID: 30444686; PMCID: PMC6325354.

Hill-Kayser CE, Tochner Z, Li Y, Kurtz G, Lustig RA, James P, Balamuth N, Womer R, Mattei P, Grupp S, Mosse YP, Maris JM, Bagatell R. Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. Int J Radiat Oncol Biol Phys. 2019;104(2):401-8. Epub 2019/02/11. doi: 10.1016/j.ijrobp.2019.01.095. PubMed PMID: 30738983.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res. 2019;25(8):2560-74. Epub 2019/01/19. doi: 10.1158/1078-0432.CCR-18-0432. PubMed PMID: 30655315.

Maris JM, Perilongo G, Halperin EC, D'Angio CT, Carrie C, Thomas P, Kalapurakal J, Marcus KJ. In Memoriam: Giulio D'Angio, MD, May 2, 1922-September 14, 2018. Int J Radiat Oncol Biol Phys. 2019;104(3):478-80. Epub 2019/06/05. doi: 10.1016/j.ijrobp.2019.03.046. PubMed PMID: 31162050.

Maris JM, Perilongo G, Markowitz RI. Giulio (Dan) J. D'Angio, MD (1922-2018). Pediatr Radiol. 2019;49(6):837-8. Epub 2019/04/21. doi: 10.1007/s00247-019-04399-0. PubMed PMID: 31004185.

Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi KS, Maris JM, Ansari M, Gumy-Pause F. PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. J Exp Clin Cancer Res. 2019;38(1):69. Epub 2019/02/14. doi: 10.1186/s13046-019-1066-6. PubMed PMID: 30755224; PMCID: PMC6373164.

Mazul AL, Weinberg CR, Engel SM, Siega-Riz AM, Zou F, Carrier KS, Basta PV, Vaksman Z, Maris JM, Diskin SJ, Maxen C, Naranjo A, Olshan AF. Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group. Cancer Epidemiol. 2019;61:165-71. Epub 2019/07/08. doi: 10.1016/j.canep.2019.06.009. PubMed PMID: 31279991.

Oldridge DA, Truong B, Russ D, DuBois SG, Vaksman Z, Mosse YP, Diskin SJ, Maris JM, Matthay KK. Differences in Genomic Profiles and Outcomes between Thoracic and Adrenal Neuroblastoma. J Natl Cancer Inst. 2019. Epub 2019/02/23. doi: 10.1093/jnci/djz027. PubMed PMID: 30793172.

Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM, Servaes S. Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study. Clin Cancer Res. 2019. Epub 2019/07/31. doi: 10.1158/1078-0432.CCR-19-0798. PubMed PMID: 31358541.

Surrey LF, MacFarland SP, Chang F, Cao K, Rathi KS, Akgumus GT, Gallo D, Lin F, Gleason A, Raman P, Aplenc R, Bagatell R, Minturn J, Mosse Y, Santi M, Tasian SK, Waanders AJ, Sarmady M, Maris JM, Hunger SP, Li MM. Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Med. 2019;11(1):32. Epub 2019/05/28. doi: 10.1186/s13073-019-0644-8. PubMed PMID: 31133068; PMCID: PMC6537185.

Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071. PMID: 31693904. 342. Lee H, Riad A, Martorano P, Mansfield A, Samanta M, Batra V, Mach RH, Maris JM, Pryma DA, Makvandi M. PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma. J Nucl Med. 2019 Nov 1. pii: jnumed.119.233965. doi: 10.2967/jnumed.119.233965. PMID: 31676730.

Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, Berg SL, Reid JM, Fox E, Weigel BJ. Phase I Clinical Trial of the Wee1 inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase 1 Report (ADVL1312). Clin Cancer Res. 2019 Dec 19. Doi: 10.1158/1078-0432.CCR-19-3470. PMID: 31857431.

Wang L, Tan TK, Durbin AD, Zimmerman MW, Abraham BJ, Tan SH, Ngoc PCT, Weichert-Leahey N, Akahane K, Lawton LN, Rokita JL, Maris JM, Young RA, Look AT, Sanda T. ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nat Commun. 2019 Dec 9;10(1):5622. doi: 10.1038/s41467-019-13515-5. PMID: 31819055.

Lopez G, Conkrite KL, Doepner M, Rathi KS, Modi A, Vaksman Z, Farra L, Hyson E, Noureddine M, Wei JS, Smith MA, Asgharzadeh S, Seeger RC, Khan J, Guidry Auvil J, Gerhard DS, Maris JM, Diskin SJ. Structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma. bioRxiv. 2019;572248. doi: https://doi.org/10.1101/572248.

Makvandi M, Lee H, Puentes LN, Reilly SW, Rathi KS, Weng CC, Chan HS, Hou C, Raman P, Martinez D, Xu K, Carlin SD, Greenberg RA, Pawel BR, Mach RH, Maris JM, Pryma DA. Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. Mol Cancer Ther. 2019;18(7):1195-204. Epub 2019/05/11. doi: 10.1158/1535-7163.MCT-18-0837. PubMed PMID: 31072830; PMCID: PMC6606392.

Li YR, Glessner JT, Coe BP, Li J, Mohebnasab M, Chang X, Connolly J, Kao C, Wei Z, Bradfield J, Kim C, Hou C, Khan M, Mentch F, Qiu H, Bakay M, Cardinale C, Lemma M, Abrams D, Bridglall-Jhingoor A, Behr M, Harrison S, Otieno G, Thomas A, Wang F, Chiavacci R, Wu L, Hadley D, Goldmuntz E, Elia J, Maris J, Grundmeier R, Devoto M, Keating B, March M, Pellagrino R, Grant SFA, Sleiman PMA, Li M, Eichler EE, Hakonarson H. Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. Nat Commun. 2020;11(1):255. Epub 2020/01/16. doi: 10.1038/s41467-019-13624-1. PubMed PMID: 31937769.

Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019:JCO1900919. Epub 2019/08/07. doi: 10.1200/JCO.19.00919. PubMed PMID: 31386611.

Qadeer ZA, Valle-Garcia D, Hasson D, Sun Z, Cook A, Nguyen C, Soriano A, Ma A, Griffiths LM, Zeineldin M, Filipescu D, Jubierre L, Chowdhury A, Deevy O, Chen X, Finkelstein DB, Bahrami A, Stewart E, Federico S, Gallego S, Dekio F, Fowkes M, Meni D, Maris JM, Weiss WA, Roberts SS, Cheung NV, Jin J, Segura MF, Dyer MA, Bernstein E. ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell. 2019. Epub 2019/10/22. doi: 10.1016/j.ccell.2019.09.002. PubMed PMID: 31631027. 350. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019;322(8):746-55. Epub 2019/08/28. doi: 10.1001/jama.2019.11642. PubMed PMID: 31454045; PMCID: PMC6714031.

2018

Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA1, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, Meshinchi S, Hunger SP, Gerhard DS, Zhang J. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018 Feb 28. doi: 10.1038/nature25795. [Epub ahead of print]

2017

Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov S, Mackall CL, Maris JM. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017;32(3):295–309. [Epub ahead of print]

Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2017;23(7):1785-1796.

2015

Zhang S, Wei JS, Li SQ, Badgett TC, Song YK, Agarwal S, Coarfa C, Tolman C, Hurd L, Liao H, He J, Wen X, Liu Z, Thiele CJ, Westermann F, Asgharzadeh S, Seeger RC, Maris JM, Guidry Auvil JM, Smith MA, Kolaczyk ED, Shohet J, Khan J. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2015 Dec 10. pii: S0304-3835(15)00735-1. doi: 10.1016/j.canlet.2015.11.045. [Epub ahead of print] PMID: 26683771.

Oldridge DA, Wood AC, Weichert-Leahey N, Crimmins I, Sussman R, Winter C, McDaniel LD, Diamond M, Hart LS, Zhu S, Durbin AD, Abraham BJ, Anders L, Tian L, Zhang S, Wei JS, Khan J, Bramlett K, Rahman N, Capasso M, Iolascon A, Gerhard DS, Guidry Auvil JM, Young RA, Hakonarson H, Diskin SJ, Look AT, Maris JM. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015 Dec 17;528(7582):418-21. doi: 10.1038/nature15540. Epub 2015 Nov 11. PMID: 26560027.

Schnepp RW, Khurana P, Attiyeh EF, Raman P, Chodosh SE, Oldridge DA, Gagliardi ME, Conkrite KL, Asgharzadeh S, Seeger RC, Madison BB, Rustgi AK, Maris JM, Diskin SJ. A LIN28B-RAN-AURKA signaling network promotes neuroblastoma tumorigenesis. Cancer Cell. 2015 Nov 9;28(5):599-609.

Schnepp RW, Bosse KR, Maris JM. Improving patient outcomes with cancer genomics: unique opportunities and challenges in pediatric oncology. JAMA. 2015 Sep 1;314(9):881-3.

Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015 Aug;47(8):864-71.

Maris JM, Knudson AG. Revisiting tissue specificity of germline cancer predisposing mutations. Nat Rev Cancer. 2015;15(2):65-6. PMID: 25688405.

Attiyeh EF, Maris JM. Identifying rare events in rare diseases. Clin Cancer Res. 2015;21(8):1782-5. PMID: 25424848.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015;62(6):1106-9. PMID: 25407467. PubMed Central ID: 4405429.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer. 2015;62(1):91-8. PMID: 25263539.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic Activity of PARP Inhibition by Talazoparib (673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clin Cancer Res. 2015;21(4):819-32. PMID: 25500058.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. (131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015;21(4):673-81. PMID: 25639769.

Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2015. PMID: 25809532.

2014

Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, et al. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatric blood & cancer. 2014;61(8):1493-6.

Meadows AT, Woods WG, Maris JM. The ASPHO 2014 distinguished career award goes to Dr. Beverly Lange. Pediatric blood & cancer. 2014;61 Suppl 1:A1-2.

McDaniel LD, Maris JM. The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: Lessons from MDM2. Pediatric blood & cancer. 2014.

Diskin SJ, Capasso M, Diamond M, Oldridge DA, Conkrite K, Bosse KR, et al. Rare variants in TP53 and susceptibility to neuroblastoma. Journal of the National Cancer Institute. 2014;106(4):dju047.

Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, et al. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clinical pharmacology and therapeutics. 2014;95(6):644-52.

Murakami-Tonami Y, Kishida S, Takeuchi I, Katou Y, Maris JM, Ichikawa H, et al. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell cycle. 2014;13(7):1115-31.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (Bi 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 61:158-164, 2014 (PMID 23956067).

2013

Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Caponigro G, Schnepp RW, Wood AC, Pawel B, Cole KA, Maris JM. Dual Cdk4/Cdk6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research. 19:6173-6182, 2013 (PMID 24045179).

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R. Initial Testing (Stage 1) of the Histone Deacetylase Inhibitor, Quisinostat (Jnj-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 2013 (PMID 24038993).

Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA. Initial Testing (Stage 1) of Tak-701, a Humanized Hepatocyte Growth Factor Binding Antibody, by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 2013 (PMID 24019233).

Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of Undifferentiated Subtype, Prognostic Significance of Prominent Nucleolar Formation, and Myc/Mycn Protein Expression: A Report from the Children's Oncology Group. Cancer. 119:3718-3726, 2013 (PMID 23901000).

Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged Versus Non-Purged Peripheral Blood Stem-Cell Transplantation for High-Risk Neuroblastoma (Cog A3973): A Randomised Phase 3 Trial. The Lancet Oncology. 14:999-1008, 2013 (PMID 23890779).

Hill-Kayser C, Tochner Z, Both S, Lustig R, Reilly A, Balamuth N, Womer R, Maris J, Grupp S, Bagatell R. Proton Versus Photon Radiation Therapy for Patients with High-Risk Neuroblastoma: The Need for a Customized Approach. Pediatric Blood & Cancer. 60:1606-1611, 2013 (PMID 23737005).

Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial Testing (Stage 1) of the Antibody-Maytansinoid Conjugate, Imgn901 (Lorvotuzumab Mertansine), by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer. 60:1860-1867, 2013 (PMID 23798344).

236. Wilzen A, Krona C, Sveinbjornsson B, Kristiansson E, Dalevi D, Ora I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F. ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. Mol Cancer. 2013 Jul 8;12(1):70.

Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Aug;60(8):1325-32.

Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Jun 29.

Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and Activity of Crizotinib for Paediatric Patients with Refractory Solid Tumours or Anaplastic Large-Cell Lymphoma: A Children's Oncology Group Phase 1 Consortium Study. The Lancet Oncology. 14:472-480, 2013 (PMID 23598171).

Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. The Genetic Landscape of High-Risk Neuroblastoma. Nature Genetics. 45:279-284, 2013 (PMID 23334666).

Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-Population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. Journal of the National Cancer Institute. 105:302-309, 2013 (PMID 23243203).

Capasso M, Diskin SJ, Totaro F, Longo L, Mariano MD, Russo R, Cimmino F, Hakonarson H, Tonini GP, Devoto M, Maris JM, Iolascon A. Replication of Gwas-Identified Neuroblastoma Risk Loci Strengthens the Role of Bard1 and Affirms the Cumulative Effect of Genetic Variations on Disease Susceptibility. Carcinogenesis. 34:605-611, 2013 (PMID 23222812).

Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KM, Hogarty M. Children's Oncology Group's 2013 Blueprint for Research: Neuroblastoma. Pediatric Blood & Cancer. 60:985-993, 2013 (PMID 23255319).

Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Peripheral Neuroblastic Tumors with Genotype-Phenotype Discordance: A Report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood & Cancer. 60:363-370, 2013 (PMID 22744966).

Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative Mibg Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 54:541-548, 2013 (PMID 23440556).

Chand D, Yamazaki Y, Ruuth K, Schonherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandstrom PE, Palmer RH, Hallberg B. Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis Model Mech. 2013 Mar;6(2):373-82. (PMID 23104988).

Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 May;60(5):783-90 (PMID 23335050).

Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Jul;60(7):E42-5. (PMID 23303741).

Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial Testing of the MDM2 Inhibitor Rg7112 by the Pediatric Preclinical Testing Program. Pediatric blood & cancer. 60:633-641, 2013 (PMID 22753001).

Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A Pilot Study of Tandem High-Dose Chemotherapy with Stem Cell Rescue as Consolidation for High-Risk Neuroblastoma: Children's Oncology Group Study ANBL00P1. Bone Marrow Transplantation. 2013 (PMID 23334272).

Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, Pawel B, Shumway SD, Maris JM, Cole KA. Combination Therapy Targeting the Chk1 and Wee1 Kinases Shows Therapeutic Efficacy in Neuroblastoma. Cancer Research. 73:776-784, 2013 (PMID 23135916).

Mayes PA, Degenhardt YY, Wood A, Toporovskya Y, Diskin SJ, Haglund E, Moy C, Wooster R, Maris JM. Mitogen-Activated Protein Kinase (Mek/Erk) Inhibition Sensitizes Cancer Cells to Centromere-Associated Protein E Inhibition. International Journal of Cancer. 132:E149-157, 2013 (PMID 22948716).

2012

Diskin SJ, Capasso M, Schnepp RW, Cole KA, Attiyeh EF, Hou C, Diamond M, Carpenter EL, Winter C, Lee H, Jagannathan J, Latorre V, Iolascon A, Hakonarson H, Devoto M, Maris JM. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012 Oct;44(10):1126-30. PubMed PMID: 22941191; PubMed Central PMCID: PMC3459292.

2011

Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, Laudenslager M, Wood AC, Mayes PA, Jagannathan J, Winter C, Mosse YP, Maris JM. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41. PubMed PMID: 21289283; PubMed Central PMCID: PMC3044382.

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, Cole K, Toporovskaya Y, Zhao H, Carpenter EL, Christensen JG, Maris JM, Lemmon MA, Mossé YP. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011 Nov 9;3(108):108ra114. PubMed PMID: 22072639; PubMed Central PMCID: PMC3319004.

Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen L, Jagannathan J, Saeki N, Sasaki H, Grant SF, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW, London WB, Capasso M, Rahman N, Hakonarson H, Maris JM. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011 Jan 13;469(7329):216-20. PubMed PMID: 21124317; PubMed Central PMCID: PMC3320515.

2010

a. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34. PubMed PMID: 20879881; PubMed Central PMCID: PMC3086629.

2008

Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):930-5. PubMed PMID: 18724359; PubMed Central PMCID: PMC2672043.

Raabe EH, Laudenslager M, Winter C, Wasserman N, Cole K, LaQuaglia M, Maris DJ, Mosse YP, Maris JM. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 2008 Jan 17;27(4):469-76. PubMed PMID: 17637745.

Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, Asgharzadeh S, Attiyeh EF, Diskin SJ, Laudenslager M, Winter C, Cole KA, Glessner JT, Kim C, Frackelton EC, Casalunovo T, Eckert AW, Capasso M, Rappaport EF, McConville C, London WB, Seeger RC, Rahman N, Devoto M, Grant SF, Li H, Hakonarson H. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008 Jun 12;358(24):2585-93. PubMed PMID: 18463370; PubMed Central PMCID: PMC2742373.

2005

Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, McGrady PW, Seeger RC, Look AT, Shimada H, Brodeur GM, Cohn SL, Matthay KK, Maris JM. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005 Nov 24;353(21):2243-53. PubMed PMID: 16306521.

2004

Mosse YP, Laudenslager M, Khazi D, Carlisle AJ, Winter CL, Rappaport E, Maris JM. Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004 Oct;75(4):727-30. PubMed PMID: 15338462; PubMed Central PMCID: PMC1182065.

2024

Teresa Maiorino, Marianna Avitabile, Vito Alessandro Lasorsa, Annalaura Montella, Sueva Cantalupo, Matilde Tirelli, Martina Morini, Alessandra Eva, Marianna Caterino, Margherita Ruoppolo, John M Maris, Sharon J Diskin, Achille Iolascon, Mario Capasso. Post-GWAS functional analysis of the 11p11.2 risk locus identifies HSD17B12 as a neuroblastoma susceptibility gene involved in lipid metabolism. The 4th International Electronic Conference on Cancers. March 2024.

Richard Gorlick, Jonathan Gill, Wendong Zhang, Yael P. Mossé, John M. Maris, David Groff, Malcolm A. Smith, Beverly Teicher, Steve Neuhauser, Tim Stearns, Vivek Philip, Emily Jocoy, Jeff Chuang, Carol J. Bult, Peter J Houghton, Raushan Kurmasheva. In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): an update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program. American Association for Cancer Research. April 2024.

Leonora R. Slatnick, Navin Pinto, Arlene Naranjo, Jed G Nuchtern, Edward F Attiyeh, Clare J. Twist, Julie R. Park, Meredith S. Irwin, Steven G. DuBois, John M. Maris, Mary Lou Schmidt, Elizabeth Fox, Araz Marachelian, E. Stanton Adkins, Michael Armstrong, Peter E Zage, Christopher Weldon, Rochelle Bagatell, Holly J. Meany. Impact of an Objective Scoring System on Initiation of Therapy in Patients with International Neuroblastoma Risk Group Staging System (INRGSS) Stage MS Neuroblastoma: A Report from the Children’s Oncology Group. American Society for Clinical Oncology. June 2024.

Peiyao Li, Richa Kapoor, John M. Maris, Diego Assis, Matthew Willetts, Hossein Fazelinia, Lynn A Spruce. Maximizing immunopeptide identification and reproducibility from minute pediatric solid tumor biopsy samples. American Society for Mass Spectrometry. June 2024.

Hasan Babazada, Paul Martorano, Hsiaoju Lee, Sarah B Gitto, Nico Ihewulezi, Vandana Batra, John M Maris, Michael D Farwell, Daniel A Pryma. PARP1-targeted alpha therapy enhances target expression. European Association of Nuclear Medicine. October 2024.

Peiyao Li, Richa Kapoor, John M. Maris, Diego Assis, Matthew Willetts, Hossein Fazelinia, Lynn A Spruce. Maximizing immunopeptide identification and reproducibility from minute pediatric solid tumor biopsy samples. Human Proteome Organization. October 2024.

Kristine S. Corkum, Holly J. Meany, Jed G. Nuchtern, Navin Pinto, Arlene Naranjo, Edward F. Attiyeh, Rochelle Bagatell, Clare J. Twist, Meredith S. Irwin, Steven G. DuBois, John M. Maris, Mary Lou Schmidt, Araz Marachelian, E. Stanton Adkins, Michael Armstrong, Peter E. Zage, Christopher Weldon, Julie R. Park, Dave R. Lal. Impact of diagnostic biopsy technique on the adequacy of biologic data required to risk-stratify patients with non-high-risk neuroblastoma: a report from the Children’s Oncology Group. International Society of Paediatric Oncology. October 2024.

2023

Amber K. Weiner, Hemma Murali, Rawan Shraim, Karina L. Conkrite, Alexander B. Radaoui, Dan Martinez, Brian Mooney, Sandi Spencer Miko, Gian Negri, Alberto Delaidelli, Caitlyn de Jong, Yuankun Zhu, Allison P. Heath, Jennifer Pogoriler, Yael P. Mosse, Deanne M. Taylor, Poul H. Sorensen, Gregg B. Morin, Benjamin A. Garcia, John M. Maris, and Sharon J. Diskin. PIONEER: Harnessing multi-omics data to enhance immunotherapeutic target discovery and development. US Human Proteome Organization Annual Conference. February 2023.

Erin Runbeck, Nick Hartnett, Keelan O’Reilly, Quinlen F. Marshall, Ben R. Kiefel, Matt Beasley, Mark Yarmarkovich, John M. Maris. Peptide-centric CAR T cell therapy targeting the tumor-associated antigen PRAME. Cancer Grand Challenges Summit 2023. March 2023.

Amber K Weiner, Hemma Murali, Rawan Shraim, Karina Conkrite, Alexander Radaoui, Dan Martinez, Brian Mooney, Sandi Spencer Miko, Gian Negri, Yuankun Zhu, Allison Heath, Caitlyn de Jong, Jenny Poglier, Gregg Morin, Poul Sorensen, Yael Mosse, Benjamin A Garcia, John M Maris, Sharon J Diskin. PIONEER: Harnessing multi-omics data to enhance immunotherapeutic target discovery and development. American Association of Cancer Research. April 2023.

Jarrett Lindsay, Minu Samanta, Nathan Kendsersky, Jonathan Gaither, Charlotte Christie, Kyabeth Torres-Rodriguez, Catherine Wingrove, and John M. Maris. ALCAM promotes neuroblastoma proliferation, migration, and immune evasion. American Association of Cancer Research. April 2023.

Liron D. Grossmann, Yasin Uzun, Mark Gerelus, Adam Wolpaw, Chia-Hui Chen, Kevin Louault, Laura Scolaro, Anusha Thadi, Peng Gao, Matteo Calafatti, Khushbu Patel, Alvin Farrel, Rebecca Kauffman, Alex Lobin, Smita Matkar, Erin Runbeck, Nathan M. Kendsersky, Jarrett Lindsay, Quinlen Marshall, Lea F. Surrey, Daniel Martinez, Colleen Casey, Kateryna Krytska, Matthew Tsang, David Groff, Emily Mycek, Jayne McDevitt, Tasleema Patel, Kathrin M. Bernt, Yves DeClerck, Shahab Asgharzadeh, Yael P. Mossé, Kai Tan, and John M. Maris. The landscape of persister cells in high-risk neuroblastoma. The American Society of Pediatric Hematology/Oncology Annual Conference. May 2023.

Yi Sun, Tyler F. Florio, Sagar Gupta, Samuel E. Garfinkle, Michael C. Young, Georgia F. Papadaki, Leena Malik, Hau V. Truong, Quinlen F. Marshall, Matthew D. Beasley, Ben R. Kiefel, Mark Yarmarkovich, John M. Maris, Nikolaos G. Sgourakis. Structural principles of peptide-centric Chimeric Antigen Receptor recognition inform therapeutic expansion. The American Association of Immunologists Annual Conference. May 2023.

Kristopher R. Bosse, Whitney Gladney, Anna Maria Guidice, Guillem Pascual-Pasto, Brendan McIntyre, Jessica Foster, Samantha N. Buongervino, Maria Lane, Karen Chagin, Thomas J. Fountaine, Vijay Peddareddigari, Dan Martinez, Charles-Antoine Assenmacher, Enrico Radaelli, Bruce Pawel, Stephen Grupp, Dave Barrett, John M. Maris. GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Erin K. Barr, Arlene Naranjo, Clare Twist, Sheena C. Tenney, Mary Lou Schmidt, Wendy B. London, Julie Gastier-Foster, E. Stanton Adkins, Peter Mattei, Michael Handler, Kathrine K. Matthay, Julie R. Park, John M. Maris, Ami V. Desai, Susan L. Cohn. Long-term Follow-up of a Phase III Study Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report from the Children’s Oncology Group Study ANBL053. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Quinlen F. Marshall, Wei Li, Richa Kapoor, Peiyao Li, Dimiter S. Dimitrov, John M. Maris, Mark Yarmarkovich. Library-based Discovery of Peptide-centric CAR T Cells for Neuroblastoma (NB). Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Catherine L. Wingrove1, Jarrett Lindsay1, Nathan Kendsersky1, Kyabeth Torres-Rodriguez1, John M. Maris. Defining the mechanisms of B7-H3 overexpression and role in neuroblastoma metastasis and immune evasion. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Liron D. Grossmann, Yasin Uzun, Mark Gerelus, Adam Wolpaw, Chia-Hui Chen, Kevin Louault, Laura Scolaro, Anusha Thadi, Peng Gao, Matteo Calafatti, Khushbu Patel, Alvin Farrel, Rebecca Kauffman, Alex Lobin, Smita Matkar, Erin Runbeck, Nathan M. Kendsersky, Jarrett Lindsay, Quinlen Marshall, Lea F. Surrey, Daniel Martinez, Colleen Casey, Kateryna Krytska, Matthew Tsang, David Groff, Emily Mycek, Jayne McDevitt, Tasleema Patel, Kathrin M. Bernt, Yves DeClerck, Shahab Asgharzadeh, Yael P. Mossé, Kai Tan, and John M. Maris. Identification, characterization, and therapeutic targeting of chemotherapy resistant high-risk neuroblastoma persister cells. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

David Groff, Colleen Casey, Kateryna Krytska, Matthew Tsang, Christina Acholla, John M. Maris, Yael P. Mosse. Dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition is potently effective in preclinical models of neuroblastoma (NB). Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Mark Yarmarkovich, Quinlen F. Marshall, Sagar Gupta, Peiyao Li, David Groff, Nikolaos Sgourakis, John M. Maris. Targeting PHOX2B with CAR T cells: progress Progress from peptide discovery to clinical trial. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Rosenberg MI, Greenstein E, Buchkovich M, Peres A, Mikl M, Santoni-Rugiu E, Yang L, Vaksman Z, Gibbs DL, Reshef D, Salovin A, Irwin MS, Naranjo A, Ulitsky I, de Alarcon PA, Matthay KK, Weigman V, Yaari G, Panzer JA, Friedman N, and Maris JM. Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma associated with opsoclonus myoclonus ataxia syndrome (OMAS). Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Esther R. Berko, Alexander A. Daniels, Samantha N. McNulty, Sheena Tenney, Grace Polkosnik, Balakrishna Koneru , Meredith S. Irwin, Rochelle Bagatell, Steven G. DuBois, John M. Maris, Arlene Naranjo, C. Patrick Reynolds, Julie R. Park, and Yael P. Mossé. Frequency and clinical significance of subclonal and clonal driver mutations in high-risk neuroblastomas at diagnosis: A Children’s Oncology Group Study. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Kyabeth Torres-Rodriguez, Mykaela Salvacion, Adam Wolpaw, Laura Scolaro, Irene Felipe, Jarrett Lindsay, Catherine Wingrove, Michael Betts, and John Maris. The impact of MYCN depletion on neuroblastoma cell survival and immune evasion. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Minu Samanta, Tingtang Wang, Khushbu Patel, Alvin Farrel, Anna Maria Giudice, Ruoning Wang, and John M. Maris. Developing immunocompetent mouse models of neuroblastoma for preclinical patient-relevant drug efficacy and I/O studies. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Erin Runbeck, Nick Hartnett, Keelan O’Reilly, Quineln Marshall, Ben R. Kiefel, Matt Beasley, Mark Yarmarkovich and John M. Maris. Peptide-centric CAR T cell therapy targeting the tumor-associated antigen PRAME. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Alexander A. Daniels, Smita Matkar, Sina Jostes, Anisha Cooke, Felix Rosemann, April Cook, Skye Balyasny, Emily Bernstein, C. Patrick Reynolds, John M. Maris, and Yael P. Mossé. The EZH2 inhibitor PF-06821497 Demonstrates High Specificity and Potency Against ALT-positive Neuroblastoma. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Kristopher R. Bosse, Michael P. Randall, Laura E. Egolf, Zalman Vaksman, Minu Samanta, Matthew Tsang, David Groff, J. Perry Evans, Jo Lynne Rokita, John M. Maris, and Sharon J. Diskin. BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. Advances in Neuroblastoma Research Association Annual Conference. May 2023.

Peiyao Li, Richa Kapoor, Mark Yarmarkovich, Alvin Farrel, Lynn A Spruce, Hossein Fazelinia, Leanne Sayles5, Mark Yarmarkovich, Alejandro Sweet-Cordero, and John M. Maris. Immunopeptidomic Profiling of Osteosarcoma Identifies Targets for Cellular Therapies. Cancer Grand Challenges Future Leaders Conference. June 2023.

Gintvile Valinciute, Lorenz Eing, Jeffrey Mihalic, Collen E. Casey, Hua Tian, Bikash Adhikari, Cristiana Guiducci, Ryan Rountree, Gwenn M. Hansen, John M. Maris, Yael P. Mossé, Martin Eilers, Elmar Wolf, and Martine F. Roussel. Chimeric Aurora A kinase degraders efficiently target MYCN. Society for NeuroOncology Annual Conference. June 2023.

Christine Hill-Kayser, Yimei Li, Goldie Kurtz, Robert Lustig, Peter Mattei, Frank Balis, Suzanne MacFarland, Vandana Batra, Yael Mosse, John Maris, Naomi Balamuth, Rochelle Bagatell. Survival and local recurrence risk rate in patients with high-risk neuroblastoma treated with proton therapy over a 10-year interval. American Society for Therapeutic Radiology and Oncology. October 2023.

Christine Hill-Kayser, Goldie Kurtz, Naomi Balamuth, Robert Lustig, Frank Balis, Suzanne Macfarland, Vandana Batra, Yael P. Mosse, John M. Maris, Sogol Mostoufi-Moab, Jill Ginsberg, Rochelle Bagatell. Efficacy & Toxicity of External Beam Radiotherapy (EBRT) for Metastatic Sites (MS) in Patients with High-Risk Neuroblastoma (HR-NBL). International Society of Paediatric Oncology Annual Conference. October 2023.

2024

Maris JM. June 11, 2024: Strategies and progress towards targeting intracellular oncoproteins with cellular immunotherapies. Cellular Immunotherapy for Pediatric Oncology Conference, Memphis, TN.

Maris JM. September 11, 2024: Discovery and clinical translation of oncofetal immunotherapy targets for childhood cancer. Parker Institute for Cancer Immunotherapy semi-annual meeting, Santa Barbara, CA.

2023

Maris JM. January 10, 2023: Targeting intracellular oncoproteins with peptide-centric cellular therapies. Mechanistic and Translational Aspects of Antigen Presentation Virtual Symposium. Berlin, Germany.

Maris JM. February 15, 2023: Progress towards cellular therapies for childhood solid cancers. Abramson Family Cancer Research Institute Members Seminar Series, University of Pennsylvania, Philadelphia, PA.

Maris JM. February 21, 2023: Immunotherapeutic target discovery and development for childhood cancers. San Antonio Pediatric Cancer Symposium Keynote Lecture, San Antonio, TX.

Maris JM. March 16, 2023: Proteogenomic approaches to create new immunotherapies targeting cancer vulnerabilities. Lankenau Institute for Medical Research Seminar Series, Wynnewood, PA.

Maris JM. April 15, 2023: Leveraging developmental biology to identify optimal immunotherapeutic targets for childhood cancers. American Association for Cancer Research Annual Meeting Education Session (Chair), Orlando, FL.

May 22, 2023: Proteogenomic approaches to create new immunotherapies for childhood cancers. CHU Sainte-Justine Universite de Montreal, Canada (Virtual).

2022

Maris JM. March 1st, 2022: Leveraging developmental biology to engineer immunotherapies for childhood cancers. Pediatric Engineering Seminar at Drexel University, Virtual.

Maris JM. April 28, 2022: Challenges and opportunities in developing new therapies for childhood cancers. Dunbar Lectureship, Louisville, KY.

Maris JM. April 29, 2022: Discovering and developing new immunotherapies for children with cancer. Dunbar Lectureship – Pediatric Ground Rounds. Louisville, KY.

Maris JM. June 28, 2022: Immunotherapeutic targeting of lineage restricted oncoproteins for childhood cancers. Seminars in Oncology, Dana-Farber Cancer Institute, and the Dana-Farber/Harvard Cancer Center, Virtual.

Maris JM. September 9, 2022: Designing and developing pediatric cancer-specific immunotherapies. The Science of Childhood Cancer Series, St. Jude Children’s Research Hospital, Virtual.

Maris JM. September 22, 2022: Neuroblastoma. ASPHO-COG CME Symposium to honor Daniella Gerhard, Virtual.

Maris JM. December 9, 2022: Engineering immunotherapies for childhood cancer. 4th Immune Modulation and Engineering Symposium, Drexel University.

2019

Foster JB, Madsen PJ, Hegde M, Ahmed N, Cole KA, Maris JM, Resnick AC, Storm PB, Waanders AJ. Immunotherapy for pediatric brain tumors: past and present. Neuro Oncol. 2019;21(10):1226-38. Epub 2019/09/11. doi: 10.1093/neuonc/noz077. PubMed PMID: 31504801; PMCID: PMC6784275.

2015

Maris JM and Shusterman S. Neuroblastoma. In Holland JC and Frei E (eds), Cancer Medicine, 7th Edition, BC Decker, Lewiston, NY, in press.

Attiyeh E and Maris JM: Hepatoblastoma: In Brodeur GM and Manno CS (eds), Requisites in Pediatrics: Hematology and Oncology, Elsevier Health Sciences, Philadelphia, PA, in press.

2011

Brodeur GM, Hogarty MD, Mosse YP and Maris JM: Neuroblastoma. In Pizzo PA and Poplack DG (eds), Principles and Practice of Pediatric Oncology, 6th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp. 886-923, 2011.

2006

Brodeur GM and Maris JM: Neuroblastoma. In Pizzo PA and Poplack DG (eds), Principles and Practice of Pediatric Oncology, 5th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp. 933-970, 2006.

2003

Maris JM and Shusterman S. Neuroblastoma. In Holland JC and Frei E (eds), Cancer Medicine, 6th Edition, BC Decker, Lewiston, NY, 2263-2376, 2003.

Fang J, Stern JW, Shusterman S, Alcorn K, Pierson G, Barr R, Pawel B, Diller L, Maris JM, and Grupp SA.  In Berdel WE, Jurgens H, Buchner Th, Ritter J, Kienast J, Vormoor J (eds), Transplantation in Hematology and Oncology II, Springer-Verlag Berlin Heidelberg, pp 283-298, 2003. 

2002

Maris JM, Matthay KK and Sondel PM: Current and future treatment strategies for high-risk neuroblastoma. ASCO Education Book 2002, 497-511, 2002.

Brodeur GM and Maris JM: Neuroblastoma. In Pizzo PA and Poplack DG (eds), Principles and Practice of Pediatric Oncology, 4th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, pp. 895-937, 2002.

Brodeur GM and Maris JM: Neuroblastoma. In Rudolph AM, Rudolph CD, Siegel NJ, Lister G and Hostetter MK (eds), Rudolph’s Pediatrics, 21st Edition, Appleton & Lange, Stamford, CT, pp. 1617-1620, 2002.

2001

Maris JM and Brodeur GM: Genetics of neuroblastoma. In Cowell J (ed), Molecular Genetics of Cancer, 2nd Edition, BIOS Publishing, Oxford, UK, pp. 335-361, 2001.

2000

Maris JM and Tonini GP: Genetics of familial neuroblastoma. Neuroblastoma, Elsevier Science, B.V., Amsterdam, pp. 125-136, 2000.

1998

Maris JM: Hepatoblastoma and hepatocellular carcinoma. In: Clinical Pediatric Gastroenterology; eds. Altschuler SA, Liacouras CA, Churchill Livingstone, Philadelphia, PA, pp. 397-404 1998.

1986

Chance B, Graham T, Maris J and Leigh JS Jr.: Resting (state 4) to active (state 3) transitions as observed by 31P NMR in steady state skeletal muscle exercise in normal human subjects.  In, Jones, N.L., McCartney, N. and McComas, A.J. (eds), Human Muscle Power, Human Kinetics Publishers, Inc. Champaign, IL, pp. 239-252, 1986.

Maris JM and Chance B: Magnetic resonance spectroscopy of neoplasms.  In, Kressel, H.Y. (ed), Magnetic Resonance Annual, Raven Press; New York, NY, pp. 213-235, 1986.

Maris JM, Evans AE, Bolinger L, McLaughlin AC, and Chance B: Analysis of the metabolism of lipid precursors in human neuroblastoma by 31P NMR spectroscopy.  In, Allen, P. and Boisvert, D.P.J. (eds), Magnetic Resonance in Cancer, Pergamon Press; Toronto, Canada, pp. 83-90, 1986.